Physician profile
Boyd Daniel Evans
NPI 1790760296
$2,185.31
in general payments reported to CMS, 2019-2025
26 companies · $542 in 2025
The $542 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.04 · 2021: $20.06 · 2022: $48.46 · 2023: $708 · 2024: $850 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,068 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,068.48 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $349.78 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $239.89 | 2024-2025 | |
| Exact Sciences Corporation | $199.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $182.30 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Idorsia Pharmaceuticals US INC | $151.45 | 2023-2024 | Quviviq |
| Pfizer INC. | $142.26 | 2023-2025 | |
| Amgen INC. | $133.92 | 2024-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $130.65 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $85.05 | 2024 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $83.17 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $53.33 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Boston Scientific Corporation | $49.34 | 2023 | Superion Indirect Decompression System |
| Astellas Pharma US INC | $45.66 | 2023-2024 | Veozah |
| Noven Therapeutics, LLC | $36.81 | 2024 | Xelstrym |
| Janssen Pharmaceuticals, INC | $36.39 | 2024 | Spravato |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $36.16 | 2024 | |
| Vivus LLC | $35.81 | 2023 | Qsymia |
| Irhythm Technologies, INC. | $25.74 | 2023 | Zio Xt Patch |
| Hologic Sales and Service, LLC | $24.61 | 2023 | Aptima |
| Takeda Pharmaceuticals U.S.A., INC. | $24.14 | 2024 | Trintellix |
| Vertex Pharmaceuticals Incorporated | $23.52 | 2025 | |
| Abbott Laboratories | $21.08 | 2023 | Freestyle Libre 2 |
| Daiichi Sankyo INC. | $20.87 | 2024 | Injectafer |
| Eisai INC. | $20.06 | 2021 | |
| Sumitomo Pharma America, INC. | $17.71 | 2025 | Gemtesa |
| Genentech USA, INC. | $16.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boyd Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.